EMA to fast-track potential 2019-nCoV treatments and vaccines


  • Dawn O'Shea
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

To contribute to the global response to the outbreak of the novel coronavirus (2019-nCoV), the European Medicines Agency (EMA) is taking action to accelerate the development and availability of medicinal products for the treatment and prevention of the new coronavirus.

EMA Executive Director Guido Rasi says the EMA has activated its plan for managing emerging health threats and is drawing on the expertise within the European medicines network to provide fast-track scientific advice and give prompt feedback on any proposed medicine developments.

In a statement this week, the agency said it is “surveying the landscape for potential antivirals or vaccines” and is analysing all available information on developers’ drug pipelines. The statement said the EMA is “ready to support medicine developers with all available regulatory tools to advance and expedite the development of effective measures to fight and prevent the spread of this virus”.

The regulatory authority is encouraging developers working on a potential treatment or vaccine to contact the EMA to discuss their strategy for evidence generation as soon as possible.